Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Raveendra KR, Chirag Rathod, Rahul Darnule, Subramanian Loganathan, Sarika Deodhar, Radhika A, Ashwani Marwah, Nitin M Chaudhari, Binay K Thakur, Sivakumar Vaidyanathan & Sandeep Nilkanth Athalye. (2023) REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT. Expert Opinion on Biological Therapy 23:5, pages 443-454.
Read now
Read now
Suresh Kumar, Rosemarie De Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah & Sandeep N. Athalye. (2021) A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opinion on Biological Therapy 21:5, pages 675-686.
Read now
Read now
Leelavathy Budamakuntla, HV Shree-Lakshmi, Akshi Bansal & Shankar Kumar Venkatarayaraju. (2019) Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India. Psoriasis: Targets and Therapy 9, pages 19-27.
Read now
Read now
Articles from other publishers (17)
Deepak Siddavaram. (2022) Successful management of cytokine storm induced acute respiratory distress syndrome secondary to H1N1 influenza with itolizumab: A case series. IP Indian Journal of Immunology and Respiratory Medicine 7:1, pages 43-46.
Crossref
Crossref
Samantha A. Chalmers, Rajalakshmy Ayilam Ramachandran, Sayra J. Garcia, Evan Der, Leal Herlitz, Jeanette Ampudia, Dalena Chu, Nicole Jordan, Ting Zhang, Ioannis Parodis, Iva Gunnarsson, Huihua Ding, Nan Shen, Michelle Petri, Chi Chiu Mok, Ramesh Saxena, Krishna R. Polu, Stephen Connelly, Cherie T. Ng, Chandra Mohan & Chaim Putterman. (2022) The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses. Journal of Clinical Investigation 132:1.
Crossref
Crossref
Neeraj Kumar, Mithun Rathinasamy, Abhyuday Kumar, Amarjeet Kumar & Kunal Singh. (2022) Severe bronchospasm following itolizumab infusion in a COVID-19 patient. Journal of Anaesthesiology Clinical Pharmacology 38:5, pages 157.
Crossref
Crossref
Rory J. Malek, Colin A. Bill & Charlotte M. Vines. (2021) Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. Biomedicine & Pharmacotherapy 144, pages 112276.
Crossref
Crossref
Xiaolong Tian, Cheng Li, Yanling Wu & Tianlei Ying. (2021) Insights into biological therapeutic strategies for COVID-19. Fundamental Research 1:2, pages 166-178.
Crossref
Crossref
Shubham Atal, Zeenat Fatima & Sadasivam Balakrishnan. (2020) Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?. BioDrugs 34:6, pages 705-711.
Crossref
Crossref
Pugazhenthan Thangaraju, Nanditha Venkatesan, Eswaran Thangaraju & Sajitha Venkatesan. (2020) Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era. SN Comprehensive Clinical Medicine 2:11, pages 2131-2136.
Crossref
Crossref
Arghadip Samaddar, Malika Grover & Vijaya Lakshmi Nag. (2020) Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. Frontiers in Pharmacology 11.
Crossref
Crossref
Stephen G. Gaffney, Elizabeth B. Perry, Ping-Min Chen, Andrew Greenstein, Susan M. Kaech & Jeffrey P. Townsend. (2019) The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget 10:44, pages 4532-4545.
Crossref
Crossref
ShrichandG Parasramani & Jisha Pillai. (2019) Biologics in psoriasis: Indian experience. Indian Journal of Drugs in Dermatology 5:1, pages 1.
Crossref
Crossref
S. Singh, D. Pradhan, P. Puri, V. Ramesh, S. Aggarwal, A. Nayek & A.K. Jain. (2019) Genomic alterations driving psoriasis pathogenesis. Gene 683, pages 61-71.
Crossref
Crossref
Lee I. Garner, Andrew Hartland, Johannes Breuning & Marion H. Brown. (2018) CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action. Immunology 155:2, pages 273-282.
Crossref
Crossref
Lingjun Zhang, Yan Li, Wen Qiu, Brent A. Bell, Nina Dvorina, William M. BaldwinIIIIII, Nora Singer, Timothy Kern, Rachel R. Caspi, David A. Fox & Feng Lin. (2018) Targeting CD6 for the treatment of experimental autoimmune uveitis. Journal of Autoimmunity 90, pages 84-93.
Crossref
Crossref
Marta Consuegra-Fernández, Feng Lin, David A. Fox & Francisco Lozano. (2018) Clinical and experimental evidence for targeting CD6 in immune-based disorders. Autoimmunity Reviews 17:5, pages 493-503.
Crossref
Crossref
Ganesh Pai & Anusha H. Pai. (2017) Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis. Case Reports in Dermatology 9:2, pages 141-145.
Crossref
Crossref
Yan Li, Nora G. SingerJoy WhitbredMichael A. BowenDavid A. Fox & Feng Lin. (2017) CD6 as a potential target for treating multiple sclerosis. Proceedings of the National Academy of Sciences 114:10, pages 2687-2692.
Crossref
Crossref
Vinay Singh. (2016) Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions. Dermatology Research and Practice 2016, pages 1-4.
Crossref
Crossref